Pharma Report Profile
Hepatitis C is so 2015 — at least, that's what Gilead Sciences CEO John Milligan is saying following his first year at the helm.
Is Pfizer finally in a position to close the Lipitor chapter, the one titled "how to bounce back from monumental loss"? All signs indicate yes.
After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.
The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.
Biotech major Amgen is making good on a lofty promise to generate $1.5 billion in savings by 2018.
The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan.
Any conversation about AbbVie has to begin with Humira, the best-selling drug in the world and the drugmaker's most important product.
Sanofi has been browsing in the acquisition aisle for some time now, even wheeling a few companies to the register only to leave empty-handed.
The FDA made patients, providers, and investors very happy when it approved Roche's Ocrevus in March.
Following one of the most anticipated exclusivity losses of the decade, sales of Novartis cancer drug Gleevec slipped 28% in 2016 to $3.3 billion.
Eli Lilly has faced a rough patch. Last November, the company took a $150 million charge over its failed high-profile Alzheimer's disease drug solanezumab.
AstraZeneca brought its internal overhaul A game in 2016, leaving investors humming the tune of a much-needed turning point.
Gilead's current and future success lies in the hands of its antiviral franchise.
J&J has earmarked a pile of cash — in the neighborhood of $18.5 billion — for future acquisition targets, but is patiently pacing the sidelines for the best players to walk onto the field.
Merck's landmark approval in 2015 was for immunotherapy Keytruda, which was cleared in October as a second-line treatment for the most common form of skin cancer.
There are two primary reasons Novartis anticipates flat sales during 2016: Its hallmark cancer drug Gleevec recently came off patent and its Alcon ophthalmic business has seen declining growth rates.
Pfizer's dream to shave the top off a rising U.S. tax bill — and level the playing field with overseas competitors — was dashed.
AstraZeneca has embarked on what's likely to be a long, rough ride.
Analysts agree that Teva is casting a healthy financial shadow.
As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer's future.
On the sales and profit forecast front, analysts say that Roche missed the mark in 2015.
The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent's sales to date haven't awed analysts.
Allergan and Pfizer agreed to scrap their pending mega-merger following an early April power play by the U.S. government.
Coming off what AbbVie's board dubbed an "exceptional year," 2016 may sting.
Diabetes drugs headlined Eli Lilly's 2015 results, with Humalog and Trulicity contributing mightily to the upward sales curve.
Novo Nordisk wants to own the obesity space much in the same way that it has attempted to dominate diabetes.
The year 2015 was one of restructuring for GlaxoSmithKline.
In an effort to overcome pricing pressures and bounce back from patent losses, Germany's second-largest drugmaker has unloaded assets and reshuffled its management team.
After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo.
Biogen's 2015 was hindered by less-than-stellar sales of its flagship multiple sclerosis treatment Tecfidera.